Form 4: Guided Therapeutics Director Boosts Stake with Stock and Warrants

Guided Therapeutics Director Michael C. James acquired additional common stock and warrants, increasing his beneficial ownership in the company.

Summary

• Michael C. James, a Director of Guided Therapeutics Inc. (GTHP), acquired additional securities on August 29, 2025.
• The transaction involved the purchase of 27,778 units, each consisting of one share of common stock and one warrant.
• The total purchase price for these units was $5,000.
• The common stock was acquired at an implied price of approximately $0.18 per share.
• The warrants are immediately exercisable, have an exercise price of $0.25 per share, and will expire on August 28, 2029.
• Following this transaction, Mr. James beneficially owns 553,495 shares of common stock directly.
• He also beneficially owns 52,778 warrants directly.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director increasing their stake in the company, signaling confidence. While the amount is relatively small, the act of insider buying is generally a bullish indicator.

Positives

• A Director increasing their stake in the company signals confidence in its future prospects.
• The acquisition of both common stock and warrants demonstrates a long-term commitment and belief in potential upside.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance from the company, as it is a report of an insider transaction.

Management Comments

• The Company entered into a Securities Purchase Agreement with Mr. James for the sale of units, each consisting of one share of common stock and one warrant.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. However, insider buying can be a positive signal within the biotechnology or medical device industry, suggesting management's belief in future product success or market growth.

Related Party Transactions

• The company entered into a Securities Purchase Agreement with Michael C. James, a Director, for the sale of common stock and warrants, constituting a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value and future prospects, potentially boosting investor confidence.
• The company received $5,000 in capital from the transaction, which could be used for general corporate purposes.

Key Dates

Recommendation

The insider buying by a director, Michael C. James, signals strong confidence in Guided Therapeutics' future. While the transaction size is modest, such an action by a key executive often precedes positive developments or reflects an undervalued stock, making it a 'buy' signal for investors looking for conviction from within the company.

Keywords

GTHP, Guided Therapeutics, Insider Buying, Director, Common Stock, Warrants, SEC Form 4, Beneficial Ownership